Skip to content

Update on the Spike Ferritin Nanoparticle (SpFN) COVID-19 Vaccine Clinical Trial at the Walter Reed Army Institute of Research

December 24, 2021

Recruitment for the clinical trial titled “SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With ALFQ Adjuvant for Prevention of COVID-19 in Healthy Adults (NCT04784767)” has been halted, yet the study status remains active per  An Army bulletin states that a soon-to-be completed analysis will provide information on the effectiveness of SpFN in humans.  This data will permit the comparison of SpFN with other emergency-use authorized COVID vaccines. A thank you goes out to all of the civilian volunteers.

The bulletin can be viewed at:

The advantage of SpFN over the other COVID vaccines is that it can provide a ferritin-based scaffold to target current and future protein targets of SARS-CoV-2 variants, as well as other coronaviruses.

From → Posts

Leave a Comment

Leave a Reply

%d bloggers like this: